rofecoxib and ml-3000
rofecoxib has been researched along with ml-3000 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Daminet, S; Fernandes, J; Martel-Pelletier, J; Moreau, M; Pelletier, JP | 1 |
| Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
| Kaur, G; Silakari, O | 1 |
Reviews
1 review(s) available for rofecoxib and ml-3000
| Article | Year |
|---|---|
Multiple target-centric strategy to tame inflammation.
Topics: Cyclooxygenase Inhibitors; Humans; Inflammation; Lactones; Lipoxygenase; Lipoxygenase Inhibitors; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrroles; Structure-Activity Relationship; Sulfones | 2017 |
Trials
1 trial(s) available for rofecoxib and ml-3000
| Article | Year |
|---|---|
Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dogs; Double-Blind Method; Duodenoscopy; Duodenum; Gastroscopy; Lactones; Lipoxygenase Inhibitors; Pyrroles; Stomach; Sulfones; Treatment Outcome | 2005 |
Other Studies
1 other study(ies) available for rofecoxib and ml-3000
| Article | Year |
|---|---|
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |